Free Trial
→ The AI Infrastructure Play Kevin O'Leary Is Backing (From The Tomorrow Investor) (Ad)tc pixel Free NRSNW Stock Alerts

NeuroSense Therapeutics (NRSNW) Competitors

$0.01 +0.00 (+27.72%)
As of 10:14 AM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare

NRSNW vs. ALVOW, APLMW, ARAV, BIAFW, and BIVIW

Should you buy NeuroSense Therapeutics stock or one of its competitors? NeuroSense Therapeutics's main competitors and comparable companies include Alvotech (ALVOW), Apollomics (APLMW), Aravive (ARAV), bioAffinity Technologies (BIAFW), and BioVie (BIVIW). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does NeuroSense Therapeutics compare to Alvotech?

NeuroSense Therapeutics (NASDAQ:NRSNW) and Alvotech (NASDAQ:ALVOW) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, profitability, media sentiment, earnings, analyst recommendations and dividends.

Company Net Margins Return on Equity Return on Assets
NeuroSense TherapeuticsN/A N/A N/A
Alvotech N/A N/A N/A

In the previous week, NeuroSense Therapeutics and NeuroSense Therapeutics both had 2 articles in the media. NeuroSense Therapeutics' average media sentiment score of 1.39 beat Alvotech's score of 0.91 indicating that NeuroSense Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
NeuroSense Therapeutics Positive
Alvotech Positive

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NeuroSense TherapeuticsN/AN/AN/AN/AN/A
Alvotech$491.95MN/AN/AN/AN/A

Summary

NeuroSense Therapeutics and Alvotech tied by winning 1 of the 2 factors compared between the two stocks.

How does NeuroSense Therapeutics compare to Apollomics?

Apollomics (NASDAQ:APLMW) and NeuroSense Therapeutics (NASDAQ:NRSNW) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, media sentiment, risk, institutional ownership, profitability and analyst recommendations.

Company Net Margins Return on Equity Return on Assets
ApollomicsN/A N/A N/A
NeuroSense Therapeutics N/A N/A N/A

In the previous week, NeuroSense Therapeutics had 1 more articles in the media than Apollomics. MarketBeat recorded 2 mentions for NeuroSense Therapeutics and 1 mentions for Apollomics. Apollomics' average media sentiment score of 1.79 beat NeuroSense Therapeutics' score of 1.39 indicating that Apollomics is being referred to more favorably in the media.

Company Overall Sentiment
Apollomics Very Positive
NeuroSense Therapeutics Positive

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Apollomics$8.50MN/AN/AN/AN/A
NeuroSense TherapeuticsN/AN/AN/AN/AN/A

Summary

Apollomics beats NeuroSense Therapeutics on 2 of the 3 factors compared between the two stocks.

How does NeuroSense Therapeutics compare to Aravive?

Aravive (NASDAQ:ARAV) and NeuroSense Therapeutics (NASDAQ:NRSNW) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, valuation, risk, earnings, profitability, institutional ownership and analyst recommendations.

In the previous week, NeuroSense Therapeutics had 2 more articles in the media than Aravive. MarketBeat recorded 2 mentions for NeuroSense Therapeutics and 0 mentions for Aravive. NeuroSense Therapeutics' average media sentiment score of 1.39 beat Aravive's score of 0.00 indicating that NeuroSense Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Aravive Neutral
NeuroSense Therapeutics Positive

35.8% of Aravive shares are owned by institutional investors. 60.4% of Aravive shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AraviveN/AN/AN/A-$0.90N/A
NeuroSense TherapeuticsN/AN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
AraviveN/A N/A N/A
NeuroSense Therapeutics N/A N/A N/A

Summary

Aravive and NeuroSense Therapeutics tied by winning 2 of the 4 factors compared between the two stocks.

How does NeuroSense Therapeutics compare to bioAffinity Technologies?

bioAffinity Technologies (NASDAQ:BIAFW) and NeuroSense Therapeutics (NASDAQ:NRSNW) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, institutional ownership, earnings, media sentiment, profitability and risk.

Company Net Margins Return on Equity Return on Assets
bioAffinity TechnologiesN/A N/A N/A
NeuroSense Therapeutics N/A N/A N/A

In the previous week, bioAffinity Technologies had 3 more articles in the media than NeuroSense Therapeutics. MarketBeat recorded 5 mentions for bioAffinity Technologies and 2 mentions for NeuroSense Therapeutics. NeuroSense Therapeutics' average media sentiment score of 1.39 beat bioAffinity Technologies' score of 0.42 indicating that NeuroSense Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
bioAffinity Technologies Neutral
NeuroSense Therapeutics Positive

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
bioAffinity Technologies$5.85MN/AN/AN/AN/A
NeuroSense TherapeuticsN/AN/AN/AN/AN/A

Summary

bioAffinity Technologies beats NeuroSense Therapeutics on 2 of the 3 factors compared between the two stocks.

How does NeuroSense Therapeutics compare to BioVie?

NeuroSense Therapeutics (NASDAQ:NRSNW) and BioVie (NASDAQ:BIVIW) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, valuation, profitability, institutional ownership, earnings and analyst recommendations.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NeuroSense TherapeuticsN/AN/AN/AN/AN/A
BioVieN/AN/AN/AN/AN/A

In the previous week, NeuroSense Therapeutics and NeuroSense Therapeutics both had 2 articles in the media. BioVie's average media sentiment score of 1.41 beat NeuroSense Therapeutics' score of 1.39 indicating that BioVie is being referred to more favorably in the news media.

Company Overall Sentiment
NeuroSense Therapeutics Positive
BioVie Positive

Company Net Margins Return on Equity Return on Assets
NeuroSense TherapeuticsN/A N/A N/A
BioVie N/A N/A N/A

Summary

BioVie beats NeuroSense Therapeutics on 1 of the 1 factors compared between the two stocks.

Get NeuroSense Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for NRSNW and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NRSNW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NRSNW vs. The Competition

Export
MetricNeuroSense TherapeuticsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market CapN/A$3.88B$7.26B$13.10B
Dividend YieldN/A3.65%2.52%22.89%
P/E RatioN/A13.21275.5425.58
Price / SalesN/A1,131.68557.6780.26
Price / CashN/A118.5077.1653.04
Price / BookN/A17.1610.816.02
Net IncomeN/A-$22.65M$3.49B$380.34M
7 Day PerformanceN/A-4.64%-3.00%-3.19%
1 Month PerformanceN/A-12.66%-7.48%-6.07%
1 Year PerformanceN/A8.08%3.18%-3.77%

NeuroSense Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NRSNW
NeuroSense Therapeutics
N/A$0.01
+27.7%		N/A-97.7%$0.00N/AN/A16
ALVOW
Alvotech
N/A$0.45
flat		N/A-70.0%$0.00$491.95MN/A4
APLMW
Apollomics
N/A$0.01
flat		N/AN/A$0.00$8.50MN/A15
ARAV
Aravive
N/A$0.04
flat		N/AN/A$0.00N/AN/A20
BIAFW
bioAffinity Technologies
N/A$0.34
-34.6%		N/A-29.4%$0.00$5.85MN/A10

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:NRSNW) was last updated on 10/14/2026 by MarketBeat.com Staff.
From Our Partners
Wall Street legend reveals his top AI stock before Oct. 20
Marc Chaikin, the 60-year Wall Street veteran behind the Power Gauge rating system, has flagged a new AI stock...
Chaikin Analytics | Sponsoredtc pixel
Trump's about to unleash his Midterm Weapon
Trump is turning the midterms into a referendum on American energy, pushing for more oil, more gas, and lower ...
Monument Traders Alliance | Sponsoredtc pixel
Elon Musk’s One Stock Retirement Plan
Jeff Brown picked Nvidia in 2016, before it surged 37,000 percent. Now he's tracking a small AI company he say...
Brownstone Research | Sponsoredtc pixel
How one AI fund pays investors every Thursday
One small fund tied to artificial intelligence stocks delivered $1,051 in a single month, not through selling ...
Investors Alley | Sponsoredtc pixel
The Iran War Isn’t Chaos. It’s Strategy.
Two thousand missiles struck Iran. Three days later, Dylan Jovine sat in two private meetings with U.S. Congre...
Behind the Markets | Sponsoredtc pixel
A letter from Shannon Stansberry
Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...
Porter & Company | Sponsoredtc pixel
Why major institutions are piling into this digital asset now
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely | Sponsoredtc pixel
Forget Biotech Stocks… This Is the Smarter Play
NVIDIA, Shopify, and TSMC built fortunes by powering innovation rather than betting on a single winner. One li...
Compounding Quality | Sponsoredtc pixel